Navigation Links
Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
Date:5/13/2009

DURHAM, N.C., May 13 /PRNewswire/ -- Addrenex Pharmaceuticals today expanded its pipeline of products aimed at adrenergic regulation with the signing of an agreement to license a new drug for the treatment of narcolepsy, a chronic and debilitating sleep disorder, as well as other neurologic and psychiatric conditions.

The agreement to license ADX-N05 gives Addrenex the worldwide rights (excluding East Asia) to develop, manufacture and commercialize the compound from SK Life Science Business Division, the drug-discovery and development division of SK Holdings Co. Ltd., one of the largest multinational companies based in South Korea.

"The partnership with SK Holdings embodies our commitment to seeking global alliances that further our goal of developing drugs for adrenergic regulation," said Steve Butts, Vice President of Commercial Operations for Addrenex Pharmaceuticals.

"We are pleased and excited to partner with an innovative, dynamic company such as SK Holdings, and we expect this to be the first of many global development partnerships for Addrenex," he added.

The licensing deal with SK Holdings provides Addrenex with its fourth drug candidate to enter clinical trials in three years. Each of Addrenex's drugs in development focuses on the treatment of medical conditions arising from an overactive or improperly regulated adrenergic system, a group of hormones and brain chemical messengers known as neurotransmitters. These hormones and neurotransmitters regulate diverse physiologic functions such as stress, pain, sleep and blood pressure.

Addrenex's lead products are Clonicel(R) for the treatment of attention-deficit hyperactivity disorder (ADHD) and Sympres(R) for the treatment of hypertension. The company also plans to develop drugs to treat menopausal flushing and potentially pain, insomnia and migraines, all of which are impacted by the adrenergic system.

'/>"/>

SOURCE Addrenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
2. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
3. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
4. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
5. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
6. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting
7. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
8. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
9. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
10. Transcept Pharmaceuticals to Report First Quarter 2009 Results
11. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/15/2014)... 15, 2014  A novel wearable injector slightly larger than an ... patients to self-inject prescription drugs in the large doses required ... diseases, autoimmune deficiencies, and genetic disorders.  An ... by 2018, according to analysts.   Many of these drugs will ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... NUREMBERG, Germany, October 13 The German ... Mobile C-arms Business,Development Strategy Leadership Award" from the independent ... successful growth strategy,of the technology leader in the area ... up of important new markets, as well as the,securing ...
... WALTHAM, Mass., Oct. 13 According to Millennium Research ... intelligence, sustained economic growth since 2003 in Brazil, Russia, ... health care expenditures with an astounding $500 billion spent ... to diagnostic imaging scanners. Findings from MRG,s newest series ...
Cached Medicine Technology:Award-Winning Medical Technology From Germany 2Award-Winning Medical Technology From Germany 3$500 Billion Health Care Spend Boosts BRIC Countries' Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group 2$500 Billion Health Care Spend Boosts BRIC Countries' Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group 3
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... synthetic biology team has created a new technology ... that could travel the body and selectively target ... cell-based, biological devices that monitor and modify human ... biology. However, no existing technology enabled bioengineers to ... state and respond in a customized fashion. , ...
(Date:4/17/2014)... who treat patients with a severe and progressive ... agonizing treatment decision. , The drug sirolimus can ... shortness of breath. But some patients eventually may ... fatal complications following transplantation. , "It,s a terrible ... of Loyola University Medical Center,s LAM Clinic and ...
(Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2
... , , , SAN DIEGO, Aug. 6 AMN Healthcare Services, Inc. (NYSE: ... months ended June 30, 2009 include: , , ... % Chg % Chg, ... Q2 2009 Q2 2008 Q1 2009, ...
... improves mood and recovery, study finds, , THURSDAY, ... to treatment with antidepressants helps improve depression and ... new study suggests. , "One-third of patients who ... less able to recover from the stroke, worsens ...
... , , OAKLAND, Calif., Aug. ... (2006), approximately 1.5 million Americans sustain traumatic brain injuries every year, ... a recent surge in interest concerning mild traumatic brain injuries (MTBI,s) ... of American troops in the Middle East. As many as ...
... Doctors should diagnose based on symptoms and strains in circulation, ... can,t rely on rapid tests to diagnose the pandemic H1N1 ... and found that they miss many infections. , The tests ... the U.S. Centers for Disease Control and Prevention reported. Sensitivity ...
... PHOENIX, Aug. 6 NutraCea (OTC: NTRZ) ... and technology, today announced the Company has entered into a forbearance ... the previously disclosed "Events of Default" which accelerated outstanding amounts due ... , , Pursuant to the terms of the ...
... , UNITED NATIONS, Aug. 6 ... Population Fund, are critical to enhancing efforts to reduce maternal ... Representatives of more than 40 international faith-based organizations emphasized ... a policy round table on a range of issues including ...
Cached Medicine News:Health News:AMN Healthcare Announces Second Quarter 2009 Results 2Health News:AMN Healthcare Announces Second Quarter 2009 Results 3Health News:AMN Healthcare Announces Second Quarter 2009 Results 4Health News:AMN Healthcare Announces Second Quarter 2009 Results 5Health News:AMN Healthcare Announces Second Quarter 2009 Results 6Health News:AMN Healthcare Announces Second Quarter 2009 Results 7Health News:AMN Healthcare Announces Second Quarter 2009 Results 8Health News:AMN Healthcare Announces Second Quarter 2009 Results 9Health News:AMN Healthcare Announces Second Quarter 2009 Results 10Health News:AMN Healthcare Announces Second Quarter 2009 Results 11Health News:AMN Healthcare Announces Second Quarter 2009 Results 12Health News:AMN Healthcare Announces Second Quarter 2009 Results 13Health News:AMN Healthcare Announces Second Quarter 2009 Results 14Health News:AMN Healthcare Announces Second Quarter 2009 Results 15Health News:AMN Healthcare Announces Second Quarter 2009 Results 16Health News:Combo Treatment May Ease Depression After Stroke 2Health News:Knowing What to Look for Can Aid in Proper Diagnosis & Treatment of Mild Traumatic Brain Injuries 2Health News:Rapid Swine Flu Test Misses Many Infections 2Health News:Rapid Swine Flu Test Misses Many Infections 3Health News:NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions 2Health News:NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions 3Health News:NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions 4Health News:NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions 5Health News:Cooperation Between Faith-Based Organizations and UNFPA Critical to Maternal Health, Say Groups 2
... developed over Guidants 20-year history, the VOYAGER ... for successful treatment outcomes. It combines a ... a lower profile shaft,more flexible markers, and ... cross tight and tortuous anatomy with even ...
... technology developed over Guidants 20-year history, the ... foundation for successful treatment outcomes. It combines ... with a lower profile shaft,more flexible markers, ... can cross tight and tortuous anatomy with ...
Test for AFP...
Enzyme Immunoassay for the Quantitative Measurement of Ovarian Cancer Antigen CA-125 in Human Serum...
Medicine Products: